February 19, 2015, 1:00 pm - 2:30 pm ET
Anticoagulation ADEs An Old Problem: A New Focus (Part 1 of 3)
In our January webinar we introduced the "Triple Threat" of Anticoagulation, Diabetic agents, and Opioid medications, and asked our audience whether they needed an in-depth review of the each of these areas. The National Action Plan for Adverse Drug Event Prevention (ADE Action Plan) published by HHS last year has brought these old problems of ADEs back into focus and is signaling the likelihood of payment incentives to prevent the enormous suffering and costs associated with them.
The interest of our Research Test Bed was overwhelmingly positive to address these ADEs, and we are excited to announce a series of three webinars that will provide an in-depth review on Anticoagulation, Opioid medications, and Diabetic Agents.
For the first of the series, we are proud to have Dr. Alan Jacobson from VA Loma Linda as our lead speaker. Dr. Jacobson is a pioneer and leader in the field of anticoagulation management, having implemented innovative strategies within the VA system to improve anticoagulation management and dramatically reducing risk with out-of-range INR and complications associated with anticoagulation therapy.
Dr. Jacobson will share his work in both the inpatient and outpatient settings, and will discuss challenges associated with the new therapeutic drugs which require less monitoring, but bring new risks. Following his presentation, we will hear from Nadine Shehab, PharmD, MPH, of the Division of Healthcare Quality Promotion, CDC, who will address the anticoagulant ADE burden and the anticoagulation safety agenda identified in the ADE Action Plan. After the presentations, they will be joined by an expert reactor panel to discuss key takeaways and respond to questions from our webinar participants.
Click here to download the combined speakers' slide set in PDF format one (1) slide per page.
Click here to download the combined speakers' slide set in PDF format four (4) slides per page.
To view the file, click the desired link (please note: the files may take several minutes to download). To save to your hard drive, right click on the link and choose "Save Target As." (In some browsers it might say "Save Link As.")
The slide set could take several minutes to download. The "four per page" slide set may download more efficiently.
Registration Information and CE Credit Information:
Register: Click here to register for this Webinar.
When:February 19, 2015 Time: 1:00 p.m.-2:30 p.m. ET
We are accepting questions now that relate to the session topics. Please e-mail any questions related to the specific session to email@example.com with the session title in the e-mail message header.
Need technical assistance with registration? Call 512-457-7605 between 9:00 a.m. and 4:30 p.m. CT.
Participants will be informed on:
Awareness: Participants will understand and be able to communicate the frequency, severity, and preventability of errors, harm, and harm due to errors in anticoagulation medication use.
Accountability: Participants will understand who is accountable for new behaviors to protect patients and caregivers from errors and harm with anticoagulation medication use.
Ability: Participants will learn the principles of importance in education, and how to enable key actors to reduce errors and harm with anticoagulation medication use.
Action: Participants will learn what direct line-of-sight actions must be taken to prevent and reduce the harm of anticoagulation medication-related adverse drug events.
CE Participation Documentation
Texas Medical Institute of Technology, approved by the California Board of Registered Nursing, Provider Number 15996, will be issuing 1.5 contact hours for this webinar.
To request a Participation Document, please click here.
Alan K. Jacobson, MD, FACC Adverse Drug Events Old Problem, New Focus: Anticoagulation
Alan K. Jacobson, MD, FACC, is a staff cardiologist and the Associate Chief of Staff for Research at the Loma Linda VA Medical Center in Southern California. A native of Canada, Dr. Jacobson has been at Loma Linda since heading south in 1977 for medical school. In addition to practicing general cardiology, Dr. Jacobson has a special interest in antithrombotic therapy.
Nadine Shehab, PharmD, MPH National Action Plan for Anticoagulant Adverse Drug Event Prevention
Dr. Nadine Shehab, PharmD, MPH, is a senior scientist with the Medication Safety Program in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Dr. Shehab provides leadership in surveillance of adverse drug events (ADEs) using a national public health surveillance system (NEISS-CADES).
Charles R. Denham, MD Welcome and Opening on Old Problem, New Focus
During Dr. Denham's business development career spanning 30 years, he and his organizations have served hundreds of innovation teams. While in practice as a radiation oncologist, he taught biomedical engineering and product development. He has taught innovation adoption, technology transfer, and commercialization in both academia and industry. He has been an adjunct Professor of Health Services Engineering at the...
Patient Safety Advocate
Dan Ford, MBA, LFACHE Patient Safety Advocate AND Discussion and Reaction to Presentation
Dan Ford, MBA, is a patient/patient safety advocate; retired Vice President of Furst Group, a healthcare executive search firm; nationally known speaker on patient safety, has served and is serving on a number of national and regional patient safety and quality, PFE and PFAC boards/committees, serves as a patient/family advisor on LEAN process improvement events at Spectrum Health, and is a writer on patient safety and leadership.
Franck Guilloteau Discussion and Reaction to Presentations
During the past 20 years with HCC Corporation, Franck Guilloteau has led multiple projects, spanning industry segments from aerospace and consumer products to software and fitness. As Chief Technology Officer, Mr. Guilloteau takes the lead role in developing Software as a Service (SaaS) offerings and knowledge management systems used by HCC's global partners, while keeping HCC on the leading edge of technological advancements in multimedia, IT, e-commerce, and product development.
U.S. Department of Health and Human Services, Office of Disease Prevention and Health Promotion. National Action Plan for Adverse Drug Event Prevention. Washington, DC: U.S. Department of Health and human Services; 2014. Available at http://www.health.gov/hai/pdfs/ADE-Action-Plan-508c.pdf.